Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Novacyt

Healthcare GB NCYT

39.5GBX
-2.0(4.82%)

Last update at 2026-06-05T15:35:00Z

Day Range

39.5043.00
LowHigh

52 Week Range

31.0054.00
LowHigh

Fundamentals

  • Previous Close 41.50
  • Market Cap25.19M
  • Volume53162
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.40100M
  • Revenue TTM19.45M
  • Revenue Per Share TTM0.28
  • Gross Profit TTM 11.22M
  • Diluted EPS TTM-0.41

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -39.43000M -28.56800M -20.05300M -9.82900M 165.17M
Minority interest - - - - -
Net income -41.75800M -28.29200M -22.20100M -9.72800M 132.42M
Selling general administrative 40.24M 4.88M 4.86M 6.81M 4.11M
Selling and marketing expenses 1.29M 0.99M 4.83M 7.03M 4.49M
Gross profit 32.07M 3.73M 5.75M 29.68M 211.13M
Reconciled depreciation -0.20200M 9.64M 7.92M 7.88M 1.30M
Ebit -34.10700M -27.88600M -16.60200M -1.36700M 167.44M
Ebitda -34.30900M -18.24300M -10.06600M -1.22100M 169.57M
Depreciation and amortization -0.20200M 9.64M 6.54M 0.15M 2.13M
Non operating income net other - - - - -
Operating income -37.34300M -29.51600M -16.60200M -1.36700M 167.44M
Other operating expenses 56.97M 41.09M 37.64M 97.15M 102.28M
Interest expense 5.12M 0.68M 0.49M 0.24M 1.61M
Tax provision -0.73200M -0.76800M 2.15M -0.10100M 32.75M
Interest income 3.03M 0.73M 0.78M 0.03M 0.05M
Net interest income -2.08700M 1.86M 0.92M -0.29900M -2.18000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.73200M -0.76800M 2.15M -0.10100M 32.75M
Total revenue 19.63M 11.58M 21.04M 95.78M 277.20M
Total operating expenses 69.42M 33.25M 22.35M 31.05M 36.20M
Cost of revenue -12.44400M 7.85M 15.29M 66.10M 66.08M
Total other income expense net -2.08700M 0.95M -3.45100M -8.46200M -2.27000M
Discontinued operations - - -3.52900M -3.52900M -3.52900M
Net income from continuing ops -38.69800M -27.80000M -22.20100M -9.72800M 132.42M
Net income applicable to common shares - - -25.73000M -9.72800M 132.42M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 70.63M 133.81M 140.90M 183.70M 234.28M
Intangible assets 17.57M 10.23M 3.12M 3.71M 4.25M
Earning assets - - - - -
Other current assets 2.93M 11.87M - 45.57M 83.32M
Total liab 22.75M 46.57M 25.68M 41.88M 83.57M
Total stockholder equity 47.88M 87.24M 115.22M 141.81M 150.71M
Deferred long term liab - - - 0.07M 0.12M
Other current liab 4.26M 25.82M 23.35M 12.56M 7.60M
Common stock 4.05M 4.05M 4.05M 4.05M 4.05M
Capital stock 4.05M 4.05M 4.05M 4.05M 4.05M
Retained earnings -11.69600M 29.90M 61.45M 87.19M 96.92M
Other liab - - 1.19M 1.53M 7.46M
Good will 2.67M 21.45M 6.65M 11.47M 17.88M
Other assets - -24.24538M 0.62M 3.35M 3.37M
Cash 30.45M 44.05M 86.97M 101.75M 91.77M
Cash and equivalents - - - - -
Total current liabilities 6.22M 29.57M 24.24M 38.90M 74.14M
Current deferred revenue - 0.93M - 24.56M 60.90M
Net debt -18.57500M -30.35000M -86.10100M -99.87600M -89.38700M
Short term debt 1.26M 1.21M 0.61M 0.42M 0.41M
Short long term debt - - - - 0.00000M
Short long term debt total 11.88M 13.70M 0.87M 1.87M 2.38M
Other stockholder equity 55.52M 53.29M 49.72M 50.57M 49.74M
Property plant equipment - - 3.27M 6.38M 3.90M
Total current assets 39.38M 86.45M 127.24M 158.78M 204.99M
Long term investments - - - - -
Net tangible assets - - 105.45M 126.63M 128.70M
Short term investments 0.00800M 0.00900M 0.00900M 0.00900M 0.00900M
Net receivables 3.71M 27.49M 25.27M 30.19M 79.59M
Long term debt - - - - 0.00000M
Inventory 2.27M 3.02M 3.03M 11.46M 29.89M
Accounts payable 0.46M 2.31M 0.28M 1.36M 5.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 2.76M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 4.05M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -0.05886M
Accumulated amortization - - - - -
Non currrent assets other 0.03M 0.00900M - 0.07M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 31.26M 47.37M 13.66M 24.91M 29.29M
Capital lease obligations 11.88M 13.70M 0.87M 1.87M 2.38M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.87500M -13.93500M -0.57700M -5.02700M -7.96500M
Change to liabilities - - 0.00000M -23.99600M 34.84M
Total cashflows from investing activities -2.93144M -13.93500M -0.57700M -5.02700M -7.96500M
Net borrowings 0.00000M -2.35500M -0.50300M -0.43200M -5.61500M
Total cash from financing activities -1.74600M -3.96700M -0.51600M -0.59900M -5.04000M
Change to operating activities - - -10.99900M -10.99900M -10.99900M
Net income -41.75800M -28.29200M -25.73000M -9.72800M 132.42M
Change in cash -13.60100M -42.91900M -14.77300M 9.98M 90.22M
Begin period cash flow 44.05M 86.97M 101.75M 91.77M 1.54M
End period cash flow 30.45M 44.05M 86.97M 101.75M 91.77M
Total cash from operating activities -9.82300M -24.99100M -13.72900M 15.69M 102.98M
Issuance of capital stock 0.03M - - 0.00000M 2.23M
Depreciation -0.20200M 9.64M 7.92M 7.88M 8.20M
Other cashflows from investing activities -0.55744M 2.01M 0.63M 0.02M 0.07M
Dividends paid - - - - -
Change to inventory 0.66M 2.55M 8.43M 18.43M -25.96600M
Change to account receivables 32.38M 3.77M - 42.75M -80.77300M
Sale purchase of stock - -0.04700M -0.01300M -0.02900M 3.21M
Other cashflows from financing activities 0.09M -1.21225M -0.50300M -0.57000M -1.95800M
Change to netincome - - 6.65M -13.77400M 41.15M
Capital expenditures 1.86M 0.67M 0.42M 4.10M 1.18M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 31.83M -6.33735M -2.56500M 37.19M -71.90100M
Stock based compensation - - - - -
Other non cash items 0.30M -0.00465M 6.65M -19.65000M 34.26M
Free cash flow -11.01000M -25.66200M -14.14500M 11.59M 101.80M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NCYT
Novacyt		 -2.0 4.82% 39.50 - - 1.30 0.59 0.55 -8.0724
SN
Smith & Nephew PLC		 14.50 1.28% 1147.00 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 -1.2 1.96% 60.00 28.20 18.73 4.84 3.41 4.35 13.85
EKF
EKF Diagnostics Holdings Plc		 -0.2 0.75% 26.40 - 34.97 2.02 1.46 1.72 7.01
CREO
Creo Medical Group PLC		 - -% 13.75 - - 199.36 0.74 6.21 8.16

Reports Covered

Stock Research & News

View All

Profile

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

Novacyt

131 Boulevard Carnot, Le Vésinet, France, 78110

Key Executives

Name Title Year Born
Mr. James Martin McCarthy CFO, Acting CEO, Company Sec. & Director 1966
Bryan Close Chief Operations Officer NA
Ms. Wendy Karban Group HR Mang. NA
Mr. David Franks Chief HR Officer NA
Paul Oladimeji Group Head of R&D NA
Mr. Gérald Ulrich Chief Exec. Officer of Bus. Devel. NA
Mr. Steve Gibson Group Financial Controller NA
Mr. Lyn Dafydd Rees CEO & Executive Director 1973
Mr. Steve Gibson CFO, Company Secretary & Director NA
Dr. Joanne Mason Chief Scientific Officer & Director 1975

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions